Skip to main content
Division of Rheumatology, Autoimmunity and Inflammation RAI

 Clinical Trials

  1. Division of Rheumatology, Autoimmunity & Inflammation
  2. Research
  3. Center for Innovative Therapy (CIT)
  4. Clinical Trials

Current Clinical Studies

If you are interested in finding out more information about a particular study, please contact the study personnel, Ms. Linda Mendoza at: lnmendoza@health.ucsd.edu

Systemic Lupus Erythematosus (SLE)

Study Type Sponsor Details Principal Investigator
Interventional AbbVie SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Kenneth Kalunian, M.D.
Interventional Feinstein Pilot Trial of Belimumab in Early Lupus Kenneth Kalunian, M.D.
Interventional Novartis SIRIUS-SLE 1: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-Care Therapy in Patients with Systemic Lupus Erythematosus Chelsey Smith, M.D.
Interventional UCB PHEONYCS FLY: A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants with Systemic Lupus Erythematosus Kenneth Kalunian, M.D.
Interventional Zenas SUNSTONE: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Systemic Lupus Erythematosus DoQuyen Huynh, M.D.

Cutaneous Lupus Erythematosus (CLE)

Study Type Sponsor Details Principal Investigator
Interventional Astra Zeneca LAVENDER: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy Arthur Kavanaugh, M.D.
Interventional Biogen AMETHYST: A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Arthur Kavanaugh, M.D.

Systemic Sclerosis (SSc)

Study Type Sponsor Details Principal Investigator
Interventional Zura Bio A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis Arthur Kavanaugh, M.D.

Lupus Nephritis (LN)

Study Type Sponsor Details Principal Investigator
Interventional AstraZeneca IRIS: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy Chelsey Smith, M.D.
Interventional NIAID VIBRANT: A Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis Kenneth Kalunian, M.D.
Interventional Novartis SIRIUS-LN: A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus nephritis Kenneth Kalunian, M.D.

Sjogren

Interventional Amgen A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS) Monica Guma, M.D., Ph.D.
Study Type Sponsor Details Principal Investigator
Interventional ArgenX UNITY: A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease Chelsey Smith, M.D..

Rheumatoid Arthritis (RA)

Interventional Gilead A Phase 1b, Randomized, Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of GS-0151 in Adult Participants With Rheumatoid Arthritis Susan Lee, M.D.
Interventional Rise Therapeutics A single and repeat dosing study of the safety, drug exposure, and clinical activity of R-2487 in patients with Rheumatoid Arthritis Monica Guma, M.D., Ph.D.
Study Type Sponsor Details Principal Investigator